DNALYTICS

Company Snapshot

Founded: 2012
Entity Type: Private
Region: Belgium
Headquarter: Louvain-la-Neuve, Wallonia, Belgium
Key Geographics: Belgium
Corporate Address: Centre Monnet – Avenue Jean Monnet, 1348 Louvain-la-Neuve, Wallonia Belgium Tel. www.dnalytics.com

Company Overview

DNAlytics, founded in 2012 as a spinoff of UCLouvain, is developing and commercializing assays for screening and patient monitoring in cancer and rheumatology.

The company’s lead liquid biopsy product is ColonoKit, a noninvasive colorectal cancer screening test in joint development with VIB. The test is based on a 23-gene expression signature in tumor educated circulating monocytes that was identified by VIB. The test can be used before colonoscopy to detect the presence of colorectal cancer.

DNALYTICS In Reports

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Discover BCC Research's report on Next-generation Sequencing Market is steadily being integrated into clinical laboratory analysis, testing, and disease diagnostics in healthcare sectors globally.

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

BCC Research Market Report says clinical next-generation sequencing (NGS) should grow from $5.9 billion in 2020 to $22.9 billion by 2025 with a (CAGR) of 31.4%.

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

BCC Market Research Report for global liquid biopsy research tools, liquid biopsy biomarkers, technologies, services and diagnostics markets.

Company's Business Segments

  • Healthcare Services : Data Mining, Statistics, Personalized Medicine, Clinical Trials, Diagnostic, Prognostic, Theranostic, Biomarkers

Applications/End User Industries

  • Healthcare
  • Hospitals
  • Diagnostics
  • Theranostics